UPDATE: Raymond James Starts FibroGen (FGEN) at Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
FibroGen (FGEN) Steals the Show at ASN, Bodes Well for Upcoming PDUFA - Stifel
October 23, 2020 6:57 AM EDTStifel analyst Annabel Samimy reiterated a Buy rating on FibroGen (NASDAQ: FGEN) after Roxadustat had an extensive presence at ASN Kidney Week. The highlight was the competitive profile and versatility of this new anemia-correcting agent (HIF-PHI) across multiple CKD patient types. The analyst... More
